Literature DB >> 29352503

In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.

Jessica P Anand1,2, Kelsey E Kochan1, Anthony F Nastase2, Deanna Montgomery2, Nicholas W Griggs1, John R Traynor1, Henry I Mosberg2, Emily M Jutkiewicz1.   

Abstract

BACKGROUND AND
PURPOSE: Agonists at μ-opioid receptors (μ-receptors) are used for pain management but produce adverse effects including tolerance, dependence and euphoria. The co-administration of a μ-receptor agonist with a δ-opioid receptor (δ-receptor) antagonist has been shown to produce antinociception with reduced development of some side effects. We characterized the effects of three μ-receptor agonist/δ-receptor antagonist peptidomimetics in vivo after acute and repeated administration to determine if this profile provides a viable alternative to traditional opioid analgesics. EXPERIMENTAL APPROACH: Three μ-receptor agonist / δ-receptor antagonist peptidomimetics, AAH8, AMB46 and AMB47, and morphine were evaluated for the development of tolerance and dependence after 5 days of twice daily treatment with escalating doses of drug (10-50 mg·kg-1 ). Antinociceptive effects were measured in the warm water tail withdrawal assay before and after repeated drug treatment. Physical dependence was evaluated by naltrexone-precipitated withdrawal jumping. The rewarding effects of AAH8 were evaluated using a conditioned place preference (CPP) assay with twice daily conditioning sessions performed for 5 days. KEY
RESULTS: Morphine, AAH8, AMB47 and AMB46 all demonstrated acute antinociceptive effects, but repeated administration only produced tolerance in animals treated with morphine and AMB46. Injection of naltrexone precipitated fewer jumps in mice treated repeatedly with AAH8 as compared with morphine, AMB47 or AMB46. Conditioning with morphine, but not AAH8, produced significant CPP. CONCLUSIONS AND IMPLICATIONS: AAH8 may be a better alternative than traditional opioid analgesics, producing antinociception with less development of tolerance and dependence and may be less rewarding than morphine.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29352503      PMCID: PMC5978946          DOI: 10.1111/bph.14148

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.

Authors:  Natalie R Lenard; David J Daniels; Philip S Portoghese; Sandra C Roerig
Journal:  Eur J Pharmacol       Date:  2007-03-03       Impact factor: 4.432

3.  Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Authors:  Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2011-07-05       Impact factor: 4.030

4.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Authors:  P J Horan; A Mattia; E J Bilsky; S Weber; T P Davis; H I Yamamura; E Malatynska; S M Appleyard; J Slaninova; A Misicka
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

5.  Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.

Authors:  D E Selley; C C Cao; Q Liu; S R Childers
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 6.  The neurobiology of addictive disorders.

Authors:  Stephen Ross; Eric Peselow
Journal:  Clin Neuropharmacol       Date:  2009 Sep-Oct       Impact factor: 1.592

7.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 8.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

9.  NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action.

Authors:  Pattipati S Naidu; Aron H Lichtman; Carey C Archer; Everett L May; Louis S Harris; Mario D Aceto
Journal:  Eur J Pharmacol       Date:  2007-03-30       Impact factor: 4.432

10.  Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

Authors:  Aubrie A Harland; Larisa Yeomans; Nicholas W Griggs; Jessica P Anand; Irina D Pogozheva; Emily M Jutkiewicz; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2015-11-13       Impact factor: 7.446

View more
  13 in total

1.  μ-Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid-induced hyperalgesia.

Authors:  Jie Sun; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Physiol       Date:  2019-01-16       Impact factor: 5.182

2.  Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.

Authors:  Sean Henry; Jessica P Anand; Jack J Twarozynski; Ashley C Brinkel; Irina D Pogozheva; Bryan F Sears; Emily M Jutkiewicz; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2020-02-10       Impact factor: 7.446

3.  Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.

Authors:  Sean P Henry; Thomas J Fernandez; Jessica P Anand; Nicholas W Griggs; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2019-04-12       Impact factor: 7.446

4.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

5.  Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists.

Authors:  Lorella Pasquinucci; Carmela Parenti; M Carmen Ruiz-Cantero; Zafiroula Georgoussi; Paschalina Pallaki; Enrique J Cobos; Emanuele Amata; Agostino Marrazzo; Orazio Prezzavento; Emanuela Arena; Maria Dichiara; Loredana Salerno; Rita Turnaturi
Journal:  ACS Med Chem Lett       Date:  2020-01-28       Impact factor: 4.345

6.  In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.

Authors:  Jessica P Anand; Kelsey E Kochan; Anthony F Nastase; Deanna Montgomery; Nicholas W Griggs; John R Traynor; Henry I Mosberg; Emily M Jutkiewicz
Journal:  Br J Pharmacol       Date:  2018-04-24       Impact factor: 8.739

7.  Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.

Authors:  Anthony F Nastase; Jessica P Anand; Aaron M Bender; Deanna Montgomery; Nicholas W Griggs; Thomas J Fernandez; Emily M Jutkiewicz; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2019-04-09       Impact factor: 7.446

8.  Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.

Authors:  Abdelfattah Faouzi; Rajendra Uprety; Ivone Gomes; Nicolas Massaly; Attila I Keresztes; Valerie Le Rouzic; Achla Gupta; Tiffany Zhang; Hye Jean Yoon; Michael Ansonoff; Abdullah Allaoa; Ying Xian Pan; John Pintar; Jose A Morón; John M Streicher; Lakshmi A Devi; Susruta Majumdar
Journal:  J Med Chem       Date:  2020-11-10       Impact factor: 7.446

Review 9.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

Review 10.  Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology.

Authors:  Rob Hill; Meritxell Canals
Journal:  Pharmacol Ther       Date:  2021-07-10       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.